CUL5 Protein, Human (sf9, His, StrepⅡ)

The CUL5 protein is a core component of the SCF-like ECS E3 ubiquitin-protein ligase complex. CUL5 Protein, Human (sf9, His, Strep) is the recombinant human-derived CUL5 protein, expressed by sf9 insect cells , with N-Strep, N-8*His labeled tag.

CUL5 protein serves as a core component in multiple SCF-like ECS (Elongin-Cullin 2/5-SOCS-box protein) E3 ubiquitin-protein ligase complexes, orchestrating the ubiquitination and subsequent proteasomal degradation of target proteins. Functioning as a scaffold protein, CUL5 likely contributes to catalysis by precisely positioning the substrate and the ubiquitin-conjugating enzyme. The functional specificity of these E3 ligase complexes relies on the distinct substrate recognition components. ECS(SOCS1) is implicated in directing the ubiquitination of JAK2, while the ECS(KLHDC1) complex is part of the DesCEND pathway, facilitating the ubiquitination and degradation of truncated SELENOS selenoprotein resulting from failed UGA/Sec decoding. Additionally, CUL5, as part of a multisubunit complex, polyubiquitinates monoubiquitinated POLR2A and may form a cell surface vasopressin receptor. In the context of microbial infection, CUL5 appears to play a role in the proteasomal degradation of p53/TP53 stimulated by adenovirus E1B-55 kDa protein.

Human

Sf9 insect cells

N-StrepⅡ;N-8*His

Q93034 (A2-A780)

/

Partial

ATSNLLKNKGSLQFEDKWDFMRPIVLKLLRQESVTKQQWFDLFSDVHAVCLWDDKGPAKIHQALKEDILEFIKQAQARVLSHQDDTALLKAYIVEWRKFFTQCDILPKPFCQLEITLMGKQGSNKKSNVEDSIVRKLMLDTWNESIFSNIKNRLQDSAMKLVHAERLGEAFDSQLVIGVRESYVNLCSNPEDKLQIYRDNFEKAYLDSTERFYRTQAPSYLQQNGVQNYMKYADAKLKEEEKRALRYLETRRECNSVEALMECCVNALVTSFKETILAECQGMIKRNETEKLHLMFSLMDKVPNGIEPMLKDLEEHIISAGLADMVAAAETITTDSEKYVEQLLTLFNRFSKLVKEAFQDDPRFLTARDKAYKAVVNDATIFKLELPLKQKGVGLKTQPESKCPELLANYCDMLLRKTPLSKKLTSEEIEAKLKEVLLVLKYVQNKDVFMRYHKAHLTRRLILDISADSEIEENMVEWLREVGMPADYVNKLARMFQDIKVSEDLNQAFKEMHKNNKLALPADSVNIKILNAGAWSRSSEKVFVSLPTELEDLIPEVEEFYKKNHSGRKLHWHHLMSNGIITFKNEVGQYDLEVTTFQLAVLFAWNQRPREKISFENLKLATELPDAELRRTLWSLVAFPKLKRQVLLYEPQVNSPKDFTEGTLFSVNQEFSLIKNAKVQKRGKINLIGRLQLTTERMREEENEGIVQLRILRTQEAIIQIMKMRKKISNAQLQTELVEILKNMFLPQKKMIKEQIEWLIEHKYIRRDESDINTFIYMA

≥ 90%, as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.